



**THE FOUNDATION
FOR SECURE
MARKETS®**

#53190

Date: September 14, 2023

Subject: CHRS1 Options - Expiration Pricing Consideration

CHRS1 (adjusted Surface Oncology, Inc. options) will be subject to special pricing consideration in expiration processing on September 15, 2023. The pricing consideration is due to the undetermined cash in lieu of fractional shares amount included in the option deliverable of CHRS1 as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

CHRS1

CHRS1 options are adjusted Surface Oncology, Inc. options, adjusted September 8, 2023 (see OCC Information Memo #53166). The deliverable of CHRS1 options is:

NEW DELIVERABLE

PER CONTRACT:

- 1) 19 Coherus BioSciences, Inc. (CHRS) Common Shares
- 2) Cash in lieu of 0.6 fractional CHRS shares

As of September 14, 2023, the SURF Exchange Agent has not determined the price to be used to determine the cash in lieu amount.

For purposes of calculating a CHRS1 price for use in expiration processing, OCC will use the following formula:

$$\text{CHRS1} = 0.196 (\text{CHRS})$$

For example, if CHRS closes at 4.68, the CHRS1 price would be:

$$\text{CHRS1} = 0.196 (4.68) = 0.92$$

This formula includes an estimate for the value of the cash in lieu amount and not the actual amount applicable in the merger.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-

800-424-7320, or email memberservices@theocc.com.